SANEGENE BIO Trademark

Trademark Overview

On Tuesday, June 27, 2023, a trademark application was filed for SANEGENE BIO with the United States Patent and Trademark Office. The USPTO has given the SANEGENE BIO trademark a serial number of 98061878. The federal status of this trademark filing is PUBLISHED FOR OPPOSITION as of Tuesday, January 27, 2026. This trademark is owned by Suzhou Sanegene Bio Co., Ltd.. The SANEGENE BIO trademark is filed in the Pharmaceutical Products category with the following description:

Pharmaceutical preparations for the treatment of various diseases, namely, rare ocular, renal, muscular, metabolic, immune system, cardiovascular, neurological and respiratory diseases, genetic disorders, chronic liver diseases, cardiovascular diseases, cancers, and viral infections; Chemical preparations for pharmaceutical or medical purposes, namely, oligonucleotide compounds for use in the targeted delivery of Ribonucleic acid interference (RNAi) therapy; Pharmaceutical preparations for use in injection for treatment of rare ocular, renal, muscular, metabolic, immune system, cardiovascular, neurological and respiratory diseases, genetic disorders, chronic liver diseases, cardiovascular diseases, cancers, and viral infections; Chemical preparations for pharmaceutical or medical purposes, namely, molecular nanoparticle complexes that act as a platform for the delivery of RNA based drugs to biological cells; Drug delivery agents consisting of oligonucleotide compounds that facilitate d...
sanegene bio

General Information

Serial Number98061878
Word MarkSANEGENE BIO
Filing DateTuesday, June 27, 2023
Status686 - PUBLISHED FOR OPPOSITION
Status DateTuesday, January 27, 2026
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, January 27, 2026

Trademark Statements

NOT AVAILABLE"BIO"
Goods and ServicesPharmaceutical preparations for the treatment of various diseases, namely, rare ocular, renal, muscular, metabolic, immune system, cardiovascular, neurological and respiratory diseases, genetic disorders, chronic liver diseases, cardiovascular diseases, cancers, and viral infections; Chemical preparations for pharmaceutical or medical purposes, namely, oligonucleotide compounds for use in the targeted delivery of Ribonucleic acid interference (RNAi) therapy; Pharmaceutical preparations for use in injection for treatment of rare ocular, renal, muscular, metabolic, immune system, cardiovascular, neurological and respiratory diseases, genetic disorders, chronic liver diseases, cardiovascular diseases, cancers, and viral infections; Chemical preparations for pharmaceutical or medical purposes, namely, molecular nanoparticle complexes that act as a platform for the delivery of RNA based drugs to biological cells; Drug delivery agents consisting of oligonucleotide compounds that facilitate delivery of a wide range of pharmaceuticals

Classification Information

International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes005, 006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateSunday, July 30, 2023
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History

Party NameSuzhou Sanegene Bio Co., Ltd.
Party Type20 - Owner at Publication
Legal Entity Type16 - Limited Liability Company
AddressSuzhou, Jiangsu 215103
CN
Party NameSuzhou Sanegene Bio Co., Ltd.
Party Type10 - Original Applicant
Legal Entity Type16 - Limited Liability Company
AddressSuzhou, Jiangsu 215103
CN

Trademark Events

Event DateEvent Description
Sunday, July 30, 2023NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Tuesday, March 12, 2024ASSIGNED TO EXAMINER
Tuesday, March 12, 2024NON-FINAL ACTION WRITTEN
Tuesday, March 12, 2024NON-FINAL ACTION E-MAILED
Tuesday, March 12, 2024NOTIFICATION OF NON-FINAL ACTION E-MAILED
Wednesday, May 8, 2024TEAS VOLUNTARY AMENDMENT RECEIVED
Friday, June 7, 2024APPLICATION EXTENSION TO RESPONSE PERIOD - RECEIVED
Friday, June 7, 2024APPLICATION EXTENSION GRANTED/RECEIPT PROVIDED
Thursday, July 18, 2024TEAS RESPONSE TO OFFICE ACTION RECEIVED
Thursday, October 24, 2024ASSIGNED TO LIE
Thursday, October 24, 2024CORRESPONDENCE RECEIVED IN LAW OFFICE
Thursday, October 24, 2024TEAS/EMAIL CORRESPONDENCE ENTERED
Tuesday, December 3, 2024EXAMINERS AMENDMENT -WRITTEN
Tuesday, December 3, 2024EXAMINERS AMENDMENT E-MAILED
Tuesday, December 3, 2024NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
Tuesday, December 3, 2024EXAMINER'S AMENDMENT ENTERED
Tuesday, December 3, 2024APPROVED FOR PUB - PRINCIPAL REGISTER
Wednesday, December 18, 2024NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Tuesday, December 24, 2024PUBLISHED FOR OPPOSITION
Tuesday, December 24, 2024OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, February 18, 2025NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Friday, August 8, 2025TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Friday, August 8, 2025ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Friday, August 8, 2025TEAS CHANGE OF CORRESPONDENCE RECEIVED
Friday, August 8, 2025TEAS WITHDRAWAL OF ATTORNEY RECEIVED-FIRM RETAINS
Wednesday, August 13, 2025TEAS PETITION TO AMEND BASIS RECEIVED
Thursday, September 25, 2025ASSIGNED TO PETITION STAFF
Thursday, September 25, 2025PETITION TO DIRECTOR - CHANGE BASIS - GRANTED
Monday, September 29, 2025NOTICE OF ALLOWANCE CANCELLED
Monday, September 29, 2025CASE RETURNED TO EXAMINATION
Monday, September 29, 2025PREVIOUS ALLOWANCE COUNT WITHDRAWN
Monday, September 29, 2025NON-FINAL ACTION WRITTEN
Monday, September 29, 2025NON-FINAL ACTION E-MAILED
Monday, September 29, 2025NOTIFICATION OF NON-FINAL ACTION E-MAILED
Friday, December 26, 2025TEAS RESPONSE TO OFFICE ACTION RECEIVED
Friday, December 26, 2025CORRESPONDENCE RECEIVED IN LAW OFFICE
Friday, December 26, 2025TEAS/EMAIL CORRESPONDENCE ENTERED
Friday, January 2, 2026APPROVED FOR PUB - PRINCIPAL REGISTER
Wednesday, January 21, 2026NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Tuesday, January 27, 2026PUBLISHED FOR OPPOSITION
Tuesday, January 27, 2026OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED

Related Keywords

sanegene diseases cardiovascular pharmaceutical preparations namely delivery cancers chronic liver viral